<?xml version="1.0" encoding="UTF-8"?>
<p id="p0040">In part 2 of the trial, 12 patients were allocated to receive intravenous infusions of JR-141 at 1.0 or 2.0 mg/kg/week. As in the dose escalation study, concentrations of JR-141 peaked at 3 hr after administration was initiated (
 <xref rid="fig2" ref-type="fig">Figure 2</xref>B).
</p>
